- Home
- TBLD vs CRMD Comparison
TBLD vs CRMD Comparison
Compare TBLD & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBLD
- CRMD
- Stock Information
- Founded
- TBLD 2021
- CRMD 2006
- Country
- TBLD United States
- CRMD United States
- Employees
- TBLD N/A
- CRMD N/A
- Industry
- TBLD Investment Managers
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- TBLD Finance
- CRMD Health Care
- Exchange
- TBLD Nasdaq
- CRMD Nasdaq
- Market Cap
- TBLD 543.1M
- CRMD 464.7M
- IPO Year
- TBLD N/A
- CRMD 2010
- Fundamental
- Price
- TBLD $18.53
- CRMD $12.14
- Analyst Decision
- TBLD
- CRMD Strong Buy
- Analyst Count
- TBLD 0
- CRMD 6
- Target Price
- TBLD N/A
- CRMD $15.00
- AVG Volume (30 Days)
- TBLD 90.6K
- CRMD 2.2M
- Earning Date
- TBLD 01-01-0001
- CRMD 05-06-2025
- Dividend Yield
- TBLD 6.74%
- CRMD N/A
- EPS Growth
- TBLD N/A
- CRMD N/A
- EPS
- TBLD N/A
- CRMD 0.28
- Revenue
- TBLD N/A
- CRMD $82,553,827.00
- Revenue This Year
- TBLD N/A
- CRMD $239.16
- Revenue Next Year
- TBLD N/A
- CRMD $53.17
- P/E Ratio
- TBLD N/A
- CRMD $43.73
- Revenue Growth
- TBLD N/A
- CRMD N/A
- 52 Week Low
- TBLD $15.79
- CRMD $3.61
- 52 Week High
- TBLD $18.64
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- TBLD 67.69
- CRMD 63.16
- Support Level
- TBLD $18.06
- CRMD $11.39
- Resistance Level
- TBLD $18.54
- CRMD $12.99
- Average True Range (ATR)
- TBLD 0.29
- CRMD 0.49
- MACD
- TBLD 0.00
- CRMD -0.10
- Stochastic Oscillator
- TBLD 91.38
- CRMD 52.25
About TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.